Product Images Desvenlafaxine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Desvenlafaxine NDC 71205-586 by Proficient Rx Lp, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
71205-586-30 - desvenlafaxine 100
Desvenlafaxine 100mg is a medication produced by Alembic Pharmaceuticals Limited. Each package has 30 film-coated, extended release tablets that are round, biconvex and have a dark brown to red color. They are debossed with L350 on one side and plain on the other. The tablets are dispensed with a medication guide that should be given to each patient. The tablets should be kept at 20°-26°C (68"77°F) and out of reach of children.*
Figure 1 - desvenlafaxine figure1
Figure 2 - desvenlafaxine figure2
This appears to be a table displaying the effect of CYP3A4 inhibitors on the drug ketoconazole. It shows the geometric mean ratio of the maximum concentration (Cmax) and area under the curve (AUC) for ketoconazole with and without the inhibitors. The values in parentheses next to the ratios are the 30% confidence intervals. However, without additional context, it is difficult to interpret the significance of the changes in Cmax and AUC.*
Figure 3 - desvenlafaxine figure3
Figure 4 - desvenlafaxine image4
The text represents a graph showing the estimated proportion of patients who experience relapse over time after randomization. The x-axis represents time in days, and the y-axis represents the percentage of patients experiencing relapse. The graph compares Desvenlafaxine Extended-Release Tablets 50mg to placebo. The data suggests that patients taking Desvenlafaxine have a lower estimated proportion of relapse compared to those taking a placebo.*
Figure 5 - desvenlafaxine image5
This appears to be a graph or chart showing the estimated proportion of patients experiencing relapse over time while taking Desvenlafaxine Extended-Release Tablets compared to placebo. The y-axis shows the percentage of patients experiencing relapse, while the x-axis shows the time to relapse in days from randomization. The chart seems to suggest that the Desvenlafaxine tablets may be more effective in preventing relapse than the placebo.*
Structure - desvenlafaxine structure1
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.